Skip to content

Study to Evaluate the Effects of XXS on Oxidative Stress in Patients With Mild or Moderate Hyperlipidemia

Randomized, Double-blind Study to Evaluate the Effects of XXS on Oxidative Stress in Patients With Mild or Moderate Hyperlipidemia and on Lipoprotein Kinetics

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02826083
Acronym
XXS SYMPA
Enrollment
182
Registered
2016-07-07
Start date
2014-11-17
Completion date
2018-01-08
Last updated
2024-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxidative Stress

Brief summary

Given preliminary data in animal (proprietary data) have shown that XXS (a mixture of natural polyphenolic extracts of edible plants) has a significant and favourable effect on oxidative stress notably with a decrease in certain markers of oxidative stress and on plasma lipid parameters, the investigator proposes to study the effect of 6 months of treatment with XXS in a controlled study against placebo in a population of persons presenting a lipid profile at the upper limit of normal.

Interventions

DIETARY_SUPPLEMENTXXS
DIETARY_SUPPLEMENTnon-XXS

Sponsors

Centre Hospitalier Universitaire Dijon
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Persons who have provided written consent * Persons aged over 18 years * Presenting LDL levels between 1.30 and 1.90 g/l and/or triglyceride levels between 1.5 and 3 g/l

Exclusion criteria

* Persons without national health insurance cover * Pregnant or breastfeeding women * Adults under guardianship * Patients with diabetes (Insulin-Dependent Diabetes (IDD) or Non-Insulin-Dependent Diabetes NIDD) * Patients with coronary artery disease * Patients with atherosclerosis * HDL\>0.80 g/l * receiving treatment with lipid-lowering agents (statins, fibrates, ezetimibe or Ω3) * Consuming vitamin supplements (A, C, E…) * Consuming oligoelements or minerals (Se, Zn, Ca…) * Renal insufficiency (creatinine clearance \< 30 ml/min calculated according to the Modification of the Diet in Renal Disease (MDRD))

Design outcomes

Primary

MeasureTime frame
Quantification of Malondialdehyde (MDA)Change from baseline at 1 month, 3 months, 6 months after treatment with XXS
Quantification of oxidized Low Density Lipoprotein (LDL)Change from baseline at 1 month, 3 months, 6 months after treatment with XXS

Secondary

MeasureTime frame
Measure of overall free-radical defences in the blood by KRL Kyrial InternationaltestChange from baseline at 1 month, 3 months, 6 months after treatment with XXS

Other

MeasureTime frame
Quantification of LDLChange from baseline at 1 month, 3 months, 6 months after treatment with XXS
Quantification of High Density Lipoprotein (HDL)Change from baseline at 1 month, 3 months, 6 months after treatment with XXS

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026